Speciality: Oncology
Description:
Welcome to this insightful discussion featuring renowned experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja as they delve into the evolving therapeutic landscape for patients with relapsed/refractory (R/R) B-cell Acute Lymphoblastic Leukemia (ALL). In this comprehensive dialogue, the panel explores cutting-edge treatment modalities, including CAR T-cell therapy, bispecific antibodies, and novel targeted agents, while emphasizing the importance of personalized approaches based on patient-specific factors such as disease biology, prior therapies, and comorbidities. The experts critically evaluate clinical trial data, real-world outcomes, and the role of hematopoietic stem cell transplantation (HSCT) in the context of modern immunotherapies, offering evidence-based recommendations for optimizing patient care.
The discussion further highlights the transformative potential of emerging therapies like blinatumomab and inotuzumab ozogamicin, alongside advancements in CAR T-cell platforms designed to improve efficacy and reduce toxicity. Dr. Singh underscores the significance of monitoring and managing cytokine release syndrome (CRS) and neurotoxicity, while Dr. Dikshit and Dr. Jain elaborate on strategies to overcome resistance mechanisms. Dr. Baveja provides insights into bridging therapies and supportive care measures essential for maintaining patient eligibility for advanced treatments. The panel concludes by addressing challenges in access to innovative therapies in resource-limited settings and advocates for collaborative efforts to enhance clinical trial participation and equitable care delivery.
This engaging session is a must-watch for hematologists, oncologists, and healthcare professionals seeking to stay updated on the latest advancements in R/R B-cell ALL management. The experts’ balanced perspectives on risk-benefit assessments, sequencing of therapies, and future directions in precision oncology provide actionable takeaways for improving patient outcomes. Don’t miss this opportunity to learn from leading minds in the field. Be sure to watch the full video and stay tuned for more thought-provoking discussions in our upcoming series!
See More Webinars @ Hidoc Webinars
1.
Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care
2.
November 2023, Medical Bulletin 04/.
3.
Chemotherapy Boosts Survival for Older Patients With TNBC
4.
Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.
5.
Distribution of fat could influence cancer risk, study suggests
1.
Bone Marrow Niche Remodeling in Hematologic Dysfunction
2.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
3.
Ferroptosis in Cancer Therapy: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
4.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
5.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation